Principals

Principal Net Worth

$249.2B

Data Flags

Susan Wojcicki deceased August 2024 (historical filings show her as officer); foundation structures confirmed via IRS 990-PF filings

Wojcicki Foundation / Anne Wojcicki

UnknownHigh Confidence

Last verified: Dec 29, 2025

Details

Source File: research/organizations/wojcicki-foundation.md
UID: fo-wojcicki-foundation

Also Known As

**Wojcicki Foundation** - Primary philanthropic vehicle**Anne Wojcicki** - Personal brand / investment vehicle**23andMe** - Primary business entity (public company)**Brin Wojcicki Foundation** - Historical joint foundation with ex-husband

Principals (8)

Sergey BrinGoogle Co-Founder, Bayshore Global ManagementOWNS

$249.2B

Susan Wojcicki (d. 2024)YouTube CEO (2014-2023)OWNS

Dennis TroperProduct Management, GoogleOWNS

Stanley Wojcicki (d. 2024)Stanford Physics ProfessorOWNS

Janet WojcickiAnthropologist & EpidemiologistOWNS

Child 2-OWNS

Esther WojcickiEducator, Journalist, AuthorOWNS

Child 1-OWNS

Team Members (2)

Anne WojcickiPresident & Chair

WORKS_AT

Susan Wojcicki (d. 2024)Treasurer & Secretary

WORKS_AT

Related Entities (1)

23andMe Holding Co.Holding Company

Type: Public company (NYSE: ME) Founded: 2006 Co-founders: Anne Wojcicki, Linda Avey, Paul Cusenza Headquarters: Sunnyvale, California Business: Direct-to-consumer genetic testing and research platform Revenue Model: DNA test kits ($99-199), subscription services, data licensing for pharmaceutical research Database: 14+ million customers genotyped (one of world's largest genetic databases) Notable Early Funding: Google invested $3.9M in 2007 (Sergey Brin connection) Total raised: ~$786M+ across multiple rounds SPAC merger with VG Acquisition Corp in 2021 Status: Struggling financially (2023-2024) Stock trading near $0.10/share (down from $17+ peak in 2021) Market cap under $200M (Dec 2024) Workforce reductions: 40% layoff in Oct 2024 (~200 employees) Exploring strategic alternatives including potential sale NYSE delisting concerns due to sustained low stock price Board crisis: All independent directors resigned Sept 2024 Therapeutics division shut down in Nov 2024 Financial sustainability in serious question